Kevin John Dean

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Industrifonden is a Venture Capital firm, a subsidiary of Government of Sweden founded in 1979. The firm is headquartered in Stockholm.

Livingston International, Inc. engages in provision of customs brokerage, transportation and integrated logistics services. Its services include customs brokerage, U.S. customs brokerage, Canadian customs brokerage, Mexican customs brokerage, freight and transportation, global trade management, trade consulting, trade technology, business process services, trade sphere and vehicle transportation services. The company was founded by Gerry Livingston in 1945 and is headquartered in Toronto, Canada.

New York Biotechnology Association, Inc. promotes the biotechnology industry. It supports the development and growth of New York State''s life science industry, and serves its members and the life science community by providing a network for public policy, industry advocacy, and community development. The company is headquartered in New York, NY.

BCB Medical Oy engages in the provision of information systems to the healthcare industry. It offers disease-specific registries, integration platform, and Omavointi services. The company was founded by Petteri Viljanen on July 2, 2003 and is headquartered in Turku, Finland.

EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.

SharpView AB is a leading supplier of image quality optimization. The company's product concept offers high diagnostic accuracy, increased patient safety and cost savings to customers within the healthcare sector. Its business objective is to deliver Image Quality Optimization with proven benefits for patients and clinicians. The company was founded in March 2007 and is headquartered in Sweden.

Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Danske Spil A/S provides lotteries and gambling services. The company was founded on July 21, 1948 and is headquartered in Brondby, Denmark.

Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.

Part of IQVIA, Inc., Pygargus AB is a Swedish company that provides market research and consulting services for the pharmaceutical sector. The company is based in Stockholm, Sweden. The company was founded by Ragnar Linder. Pygargus was acquired by IQVIA, Inc. from Ängshöken AB on December 09, 2013.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

Trialbee AB provides software solutions and services to the pharmaceutical industry. It operates as a software company which specializes in clinical trial planning and management solutions. The firm offers global pharmaceutical companies and web-based solution for patient recruitment to clinical trials. The company was founded by Carl Johan Tobias Folkesson and Per Jonas Billing in October 2010 and is headquartered in Malmo, Sweden.

Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom.

Penn State Research Foundation provides scientific research services aimed at improving human conditions. The non-profit company is based in University Park, PA.

Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark.

NuvoAir AB provides health care sevices. Its devices include air smart spirometer and disposable turbines. The company was founded by Lorenzo Consoli and is headquartered in Stockholm, Sweden.

Part of BCB Medical Oy, Health Solutions AB operates hospitals.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

Combinostics Oy develops cloud platform for quantitative assessment of brain images and for providing clinical decision support in neurological disorders. The company was founded by Lennart Thurfjell in August 2014 and is headquartered in Tampere, Finland.

EnginZyme AB is a Swedish company founded in 2014 by Samuel Härgestam, Robin Chatterjee, and Karim Engelmark Cassimjee. EnginZyme is based in Stockholm, Sweden, and has a multidisciplinary team of experts in biocatalysis, organic chemistry, enzyme and process engineering, as well as AI and machine learning. The company has developed a patented, cell-free biomanufacturing platform that combines the power of biology with the efficiencies of the chemical industry. EnginZyme aims to produce better, greener, and more affordable products sustainably. The company's enzyme immobilisation technology enables biomanufacturing without living organisms, resulting in lower costs and a smaller environmental footprint. The company has been recognized as a technology pioneer by the World Economic Forum and was selected for the Cleantech 100 list in 2022 and 2023. Karim Engelmark Cassimjee has been the CEO since 2014.

PreciseDx Ltd. is a British AI company that specializes in oncology diagnostics. The company is based in Altrincham, UK. The company leverage the analysis of morphology features from histology slides to provide more precise patient-specific risk information. The company's proprietary morphology feature array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. The company was founded in 2019. Wayne L. Brinster has been the CEO of the company since 2021.

Part of Ejendomsselskabet Hvidovre Torv Holding AS, Ejendomsselskabet Hvidovre Torv AS engages in rental of commercial real estate properties. The company is based in Aarhus, Denmark.

Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.